BioSpace News Archive

BATM (LSE: BVC) (TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has developed a new method for the rapid and comprehensive diagnosis of tuberculosis (“TB”).

Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today a new partnership with CardioNavix, LLC aimed at improving patient access to cardiac PET imaging, an important diagnostic test for the detection of coronary artery disease (CAD).

The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Australian Biotech company Servatus Biopharmaceuticals Ltd to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.

Hangzhou Tigermed Consulting Co., Ltd., a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year ended December 31, 2020.

Ms. Chen, portfolio manager at Cormorant Asset Management, and Dr. Hambleton, a physician-turned-biotech executive, bring decades of experience to their new roles

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the first patient was dosed in DESTINY-Lung02, a global phase 2 trial evaluating the safety and efficacy of ENHERTU® (trastuzumab deruxtecan) in patients with HER2 mutated metastatic non-small cell lung cancer (NSCLC) with disease recurrence or progression during or after at least one prior platinum-containing treatment regimen.

Qihan Biotechnology Co. Ltd (“Qihan” or “the Company”), a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that it has raised an additional $67 million in Series A++ financing.

Connecticut-based medical device innovator Lumendi, LLC (www.lumendi.com) has launched EZ Glide, a proprietary hydrophilic coating applied to the inner sheath of its DiLumen EIP, a double-balloon endoluminal device that aims to safely improve the navigation of the endoscope through the bowel

Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced the appointment of John Harlow as Chief Commercial Officer, effective today.

Bayer Announces Publication of Phase IV Adempas ® (riociguat) Data in The Lancet Respiratory Medicine The prospective, randomized, controlled, open-label study, which included outcomes from 226 patients with pulmonary arterial hypertension (PAH) (WHO Group 1), met its primary endpoint